Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...

Local Anesthetics: Common Agents and Their Applications

Local Anesthetics: Common Agents and Their Applications

Local anesthetics (LAs) are commonly used for various applications in medical and dental procedures. Some of the common agents used are cocaine, lidocaine, and bupivacaine.
Cocaine is an ester of benzoic acid and methylecgogine. It is used to anesthetize and vasoconstrict locally. Currently, it is used primarily for topical applications. It is beneficial for surgeries on the upper respiratory tract, providing anesthesia and shrinking the mucosa. Cocaine in the form of cocaine hydrochloride is...

Local Anesthetics: Clinical Application as Spinal Anesthesia

Local Anesthetics: Clinical Application as Spinal Anesthesia

Spinal anesthetics are given during lower abdomen and limb surgeries to block sensory and motor neurons. They are administered in the mid to low lumbar regions, primarily acting on the cauda equina's nerve roots. The blockade level depends on the local anesthetic (LA) concentration. Usually, low LA concentrations are sufficient to block sensory fibers, while only high LA concentrations block motor fibers. Other factors like injection volume and speed, the patient's posture, and the drug...

Depolarizing Blockers: Pharmocokinetics

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...

Local Anesthetics: Clinical Application as Surface, Infiltration, and Conduction Block Anesthesia

Local Anesthetics: Clinical Application as Surface, Infiltration, and Conduction Block Anesthesia

Depending on the target organ, local anesthetics (LAs) can be administered via various routes. In surface anesthesia, LAs are applied directly to the surface of the skin or mucous membranes. It is widely used for topical skin numbing before venipuncture or minor surgical procedures. Commonly used surface local anesthetics are lidocaine or benzocaine sprays or creams. Surface anesthesia occurs within 5 minutes and lasts for about 60 minutes. One of the main disadvantages of topical anesthesia is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Hyaluronic Acid Filler CPM-V ± Lidocaine for Chin Augmentation: A Randomized, Multicenter, Open-Label Post-Market Follow-Up Study.

Clinical, cosmetic and investigational dermatology·2026

Same author

See, Touch, Feel, and Express: Achieving Safe and Natural Outcomes With HA Fillers-An International Consensus.

Journal of cosmetic dermatology·2026

Same author

A Validated Assessment Scale for the Auriculocephalic Angle in Asians.

Aesthetic plastic surgery·2026

Same author

Real-World Usage of CaHA-CMC:CPM-HA Hybrid Dermal Fillers: Findings From a Delphi Panel.

Journal of cosmetic dermatology·2026

Same author

The Safety Profile of a Portfolio of Hyaluronic Acid-Based Soft Tissue Fillers Manufactured Using MACRO Technology: A Systematic Review of Clinical Evidence.

Life (Basel, Switzerland)·2026

Same author

Why, When, and How to Treat Dynamic Forehead Lines with Botulinum Toxin Type A.

Toxins·2025

Search research articles

Related Experiment Video

Updated: May 9, 2026

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

IncobotulinumtoxinA in esthetics.

Martina Kerscher¹, Yana Yutskovskaya, Timothy Corcoran Flynn

¹Division of Cosmetic Sciences, Department of Chemistry, University of Hamburg, Hamburg, Germany. martina.kerscher@uni-hamburg.de

Journal of Drugs in Dermatology : JDD

|July 11, 2013

Summary

IncobotulinumtoxinA, a unique botulinum toxin type A free of complexing proteins, demonstrates proven efficacy and safety for treating glabellar frown lines in esthetic medicine.

Area of Science:

Neurology
Dermatology
Pharmacology

Background:

IncobotulinumtoxinA is a botulinum toxin type A preparation.
It is distinguished by its absence of complexing proteins (150 kDa).
Its therapeutic applications preceded its use in esthetic medicine.

Purpose of the Study:

To discuss the characteristics of incobotulinumtoxinA.
To review clinical data supporting its use in esthetic medicine.
Focus on glabellar frown line treatment.

Main Methods:

Review of clinical trial data.
Analysis of incobotulinumtoxinA's unique protein composition.
Assessment of safety and efficacy in esthetic applications.

More Related Videos

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

Related Experiment Videos

Last Updated: May 9, 2026

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

Main Results:

IncobotulinumtoxinA is approved for glabellar frown line treatment.
Clinical trials show positive efficacy and safety findings.
The absence of complexing proteins is a key characteristic.

Conclusions:

IncobotulinumtoxinA is a safe and effective option for esthetic treatments.
Its unique composition may contribute to its clinical profile.
Further review supports its role in cosmetic dermatology.